Table 3 Treatment regimens used in the model
Treatment strategy | Treatment explanation (“A → B” indicates after developing resistance to treatment A, patients move to treatment B; “+” indicates combination therapy) |
|---|---|
BSC | No antiviral drug treatment |
LAM → BSC | LAM as first-line therapy, followed by BSC as second- and third-line therapy |
LDT → BSC | LDT as first-line therapy, followed by BSC as second- and third-line therapy |
ADV → BSC | ADV as first-line therapy, followed by BSC as second- and third-line therapy |
ETV → BSC | ETV as first-line therapy, followed by BSC as second- and third-line therapy |
TDF → BSC | TDF as first-line therapy, followed by BSC as second- and third-line therapy |
LDT + ADV → BSC | Combination therapy of LDT and ADV as first-line therapy, followed by BSC as second- and third-line therapy |
LDT + TDF → BSC | Combination therapy of LDT and TDF as first-line therapy, followed by BSC as second- and third-line therapy |
LAM → ADV → BSC | LAM as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy |
ADV → LAM → BSC | ADV as first-line therapy, followed by LAM as second-line therapy and BSC as third-line therapy |
LDT → ADV → BSC | LDT as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy |
ETV → ADV → BSC | ETV as first-line therapy, followed by ADV as second-line therapy and BSC as third-line therapy |